Gujarat Kidney & Super Speciality IPO Overview – Latest IPO to Watch
The Gujarat kidney & super speciality ipo has entered the primary market as one of the most talked-about latest IPOs in the healthcare sector. The IPO opens on December 22, 2025, and closes on December 24, 2025. It is a pure fresh issue, meaning all proceeds will go directly to the company for growth and expansion. The price band is fixed at ₹108–₹114 per share, with a face value of ₹2. Investors can apply in a lot size of 128 shares, requiring a minimum investment of approximately ₹14,592 at the upper band. The total issue size stands at around ₹250.8–₹251 crore, and the shares are proposed to be listed on both BSE and NSE, making it a strong candidate among the latest IPO listing today discussions.
Issue Allocation and Use of IPO Proceeds
In the Gujarat kidney & super speciality ipo, allocation is structured with 75% reserved for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 10% for Retail Investors. The company plans to utilize the IPO funds strategically. Key objectives include the acquisition of Parekhs Hospital in Ahmedabad, part-payment for the recently acquired Ashwini Medical Centre, and the setup of a new hospital in Vadodara. Additionally, funds will be used for advanced robotic medical equipment, debt repayment, and general corporate purposes. This clear growth-oriented utilization strengthens the IPO’s positioning among the latest IPOs in the healthcare space.
Company Profile and Operational Strength
Gujarat Kidney & Super Speciality Ltd. is a regional healthcare provider headquarters in central Gujarat, focusing on secondary and tertiary care services. Its core expertise lies in kidney care, urology, nephrology, and other super-speciality treatments. The company currently operates a network of 7 multi-speciality hospitals supported by 4 in-house pharmacies. It has a total bed capacity of approximately 490 beds, with around 340 beds operational. As of 2025, the company employs nearly 89 doctors, 332 nurses, and 338 support staff, reflecting a strong operational base that supports long-term scalability after the Gujarat kidney & super speciality ipo.
Financial Performance and Valuation Snapshot
Financially, the company has shown sharp improvement. For FY25, revenue stood at approximately ₹40.4 crore, while net profit reached around ₹9.5 crore. Growth from FY24 to FY25 was significant, indicating improving operational efficiency. In Q1 FY26, revenue was about ₹15.3 crore, with profits of nearly ₹5.4 crore. EBITDA margins remain strong at around 41%, highlighting healthy operating leverage. However, at the upper price band, the IPO is valued at a pre-IPO P/E of around 61x, which is relatively high compared to peers — an important factor for investors tracking the latest IPO listing today.
Subscription Trends, Risks, and Investor Considerations
On Day 1, the Gujarat kidney & super speciality ipo was subscribed by around 90%, indicating positive early market sentiment. Grey Market Premium (GMP) trends suggest a modest upside of roughly ₹7, translating to 6%–9%, though GMP should not be seen as a guaranteed listing indicator. Strengths include rising healthcare demand, focused expansion plans, and improving profitability. Risks include high valuation, smaller scale compared to listed peers, regulatory challenges, and limited retail allocation. Investors should evaluate their investment horizon, risk appetite, and valuation comfort before applying, especially when comparing this opportunity with other latest IPOs in the market.
Conclusion
The Gujarat Kidney & Super Speciality IPO stands out as a high-growth healthcare opportunity backed by expanding hospital infrastructure, improving financial performance, and rising demand for specialized medical services. With IPO proceeds focused on acquisitions, new hospital development, and advanced medical technology, the company is clearly positioning itself for long-term expansion. However, investors should also be mindful of the premium valuation, limited retail allocation, and execution risks associated with rapid growth. Overall, this IPO may appeal to investors with a moderate-to-high risk appetite who are looking beyond short-term listing gains and believe in India’s long-term healthcare growth story. Careful evaluation and disciplined investment planning remain key before making a decision.
Disclaimer
This blog is for educational and informational purposes only and should not be considered financial, investment, or trading advice. Stock markets are subject to risks, and past performance does not guarantee future results. Always consult a SEBI-registered financial advisor before making any investment decisions. The companies or stocks mentioned here are included solely for learning and research purposes—not as recommendations. NexGen Trade encourages readers to perform their own analysis and invest responsibly.
What is Gujarat Kidney & Super Speciality IPO?
The Gujarat Kidney & Super Speciality IPO is a fresh issue public offering by Gujarat Kidney & Super Speciality Ltd. to raise funds for hospital expansion, acquisitions, and medical infrastructure growth.
When is the Gujarat Kidney & Super Speciality IPO open for subscription?
The IPO opens on December 22, 2025, and closes on December 24, 2025. Investors must apply within this period through their trading or banking platforms.
What is the price band and lot size of this IPO?
The price band is set at ₹108 to ₹114 per share, and the minimum application size is 128 shares, requiring an investment of approximately ₹14,592 at the upper price band.
How will the company use the IPO proceeds?
Funds raised will be used for acquiring hospitals, setting up a new hospital in Vadodara, purchasing advanced robotic medical equipment, debt repayment, and general corporate purposes.
Is Gujarat Kidney & Super Speciality IPO good for long-term investment?
The IPO offers strong long-term growth potential due to rising healthcare demand and expansion plans, but investors should consider the high valuation and execution risks before investing.
Where will Gujarat Kidney & Super Speciality IPO be listed?
The shares of Gujarat Kidney & Super Speciality Ltd. are expected to be listed on both the BSE and NSE, making it accessible to a wide range of investors.
Leave a Reply